Gemtesa

Chemical Namevibegron
Dosage FormTablets (oral; 75 mg)
Drug ClassReceptor agonists
SystemUrinary
CompanyUrovant Sciences, Inc.
Approval Year2020

Indication

  • Indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Last updated on 1/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Gemtesa (vibegron) Prescribing Information.2020Urovant Sciences, Inc. Irvine, CA